News

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.
A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...
Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...
Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...